AIT Therapeutics Schedules Fiscal Year 2019 Financial Results Conference Call and Webcast
Call scheduled for Tuesday, June 25th at 4:30pm Eastern Time
GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its fiscal year ended March 31, 2019 after the market close on Tuesday, June 25, and will host a conference call and webcast at 4:30pm Eastern Time.
|Conference Call & Webcast|
|Tuesday, June 25th @ 4:30pm ET|
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The AIT NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. AIT is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
Chief Executive Officer
AIT Therapeutics, Inc.
LifeSci Advisors, LLC
(646) 597 6989
Upcoming Life Sciences Events
- November 2019
- Krakow: Life Science Open Space 2019
- December 2019
- London: The Pharma Licensing Negotiation Course
- London: Pharma-Biotech Product & Company Valuation